

## Acute Painful Episodes Vaso-occlusive Episodes (VOE) : Guidelines for Management in Children with Sickle Cell Disease

This is a CONTROLLED document for internal use only, valid only if accessed from the Policies and Procedures site.

### 1.0 Introduction


The cause of vaso-occlusive episodes (VOE) is believed to be ischemic tissue injury from the obstruction of blood flow by sickled erythrocytes. Reduced blood flow causes hypoxia and acidosis. This further increases the sickling process, leading to further hypoxia and acidosis—a cycle that eventually leads to ischemic tissue injury. Each VOE varies in intensity and duration. Infection, fever, acidosis, hypoxia, dehydration, sleep apnea, and exposure to extremes of heat and cold can precipitate episodes. Often, no cause is identified.

Painful VOE is the most frequent complication of Sickle Cell Disease. Common sites of pain include bone (extremities, dactylitis or hand/foot syndrome, back) and abdominal pain. Bone pain, the most common type of VOE, may or may not be accompanied by swelling, low-grade fever, redness, and warmth. It may be symmetrical, asymmetrical, or migratory. Dactylitis is a common presentation in infants and toddlers; back and abdominal pain are more common in older children. Abdominal pain in children with sickle cell disease is usually a simple VOE, but other diagnoses may present similarly (splenic sequestration, liver sequestration, appendicitis, pancreatitis, biliary colic and cholecystitis, urinary tract infection, pelvic inflammatory disease, etc.) and should be ruled out. In addition, pneumonia and chest crisis may present as, or accompany abdominal pain. During a severe painful episode, a patient may also develop an acute chest syndrome, or a CNS event.

Pain should be treated early and aggressively. No laboratory features are pathognomonic of VOE; diagnosis is based strictly on the history and physical examination. When treating a painful episode, the Healthcare Provider needs to be aware that concurrent illnesses such as an acute sequestration, priapism, aplastic episode, or fever/sepsis (see other protocols) may also occur, which must be dealt with concurrently.

This clinical practice guideline has been developed for the management of sickle cell patients with an acute painful episode who present to the emergency department and/or inpatient units.

## 2.0 Clinical Practice Recommendations for Management of Vaso-occlusive Episodes



### [PRINTABLE VERSION](#)

©The Hospital for Sick Children ("SickKids"). All Rights Reserved. This document was developed solely for use at SickKids. SickKids accepts no responsibility for use of this material by any person or organization not associated with SickKids. A printed copy of this document may not reflect the current, electronic version on the SickKids Intranet. Use of this document in any setting must be subject to the professional judgment of the user. No part of the document should be used for publication without prior written consent of SickKids.

### 3.0 References

1. Baskin MN, Goh XL, Heeney MM, Harper, MB. Bacteremia risk and outpatient management of febrile patients with sickle cell disease. *Pediatrics*. 2013;131(6):1035-1041.
2. Bellet PS, Kalinyak KA, Shukla R, Gelfand MJ, Rucknagel DL. Incentive spirometry to prevent acute pulmonary complications in sickle cell diseases. *N Engl J Med*. 1995;333(11):699–703.
3. Chang TP, Kriengsoontorkij W, Chan LS, Wang VJ. Predictors for bacteremia in febrile sickle cell disease children in the post-7-valent pneumococcal conjugate vaccine era. *Journal of Pediatric Hematology Oncology*. 2013;35 (5):377-382.
4. Griffen TC, McIntire D, Buchanan GR. High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. *N Engl J Med*. 1994;330(11):733–37.
5. Jacobson SJ, Kopecky EA, Joshi P, Babul N. Randomised trial of oral morphine for painful episodes of sickle-cell disease in children. *Lancet*. 1977;350:1358–61.
6. National Heart, Lung, and Blood Institute. Evidence-based management of sickle cell disease: Expert panel report, 2014.
7. Reid CD, Charache S, Lubin B (eds). *Management and Therapy of Sickle Cell Disease, 3rd edition*. National Institutes of Health Publication No 95-2117, Bethesda, Maryland, 1995.
8. Robieux IC, Kellner JD, Coppes MJ, Shaw D, Brown E, Good C, O'Brodovich H, Manson D, Olivieri NF, Zipursky A, Koren G. Analgesia in children with sickle cell crisis: comparison of intermittent opioids vs. continuous intravenous infusion of morphine and placebo-controlled study of oxygen inhalation. *Pediatr Hematol Oncol*. 1992;9:317–26.
9. Savlov D, Beck CE, DeGroot, J, Odame I, Friedman JN. Predictors of bacteremia among children with sickle cell disease presenting with fever. *Pediatr Hematol Oncol*. 2014;36(5):384-388.
10. Shapiro B. The management of pain in sickle cell disease. *Pediatr Clin North Am*. 1989;36:1029–45

### 4.0 Related documents

- [Acute Chest Syndrome or Pneumonia: Guidelines for Management in Children with Sickle Cell Disease](#)
- [Pain Assessment Policy](#)
- [Pain Management Clinical Practice Guideline](#)

#### Attachments:

[Discharge Criteria FINAL.pdf](#)

[ED medication management.pdf](#)

[Inpatient Management.pdf](#)

[Revision History.docx](#)

[SC\\_Clinic Follow Up FINAL.pdf](#)

[SCD pain plan.pdf](#)